ROPI was shown to improve ALS phenotypes in patient iPSC‐derived MNs, including neurite retraction, cell death, accumulation of abnormal protein aggregates, as well as elevated levels of reactive oxygen species (ROS) and lipid peroxidation in MNs with mutations in the TARDBP gene, mutations in the fused in sarcoma (FUS) gene, and sporadic ALS‐MNs (Fujimori et al. 2018). The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.